LCB02A: Showcasing a CLDN18.2-Targeting ADC Utilizing LigaChem Biosciences’ Site-Specific Bioconjugation & Linker Technology
11:30 am - Tuesday 13th October 2026
- Utilizing the site specific ConjuAll platform to build a discrete DAR ADC with circulation stable bioconjugation in combination with a proprietarty beta-glucuronidase linker
- Exploring how ConjuAll platform design corresponds to LCB02A’s excellent preclinical therapeutic index
- Building out a clinical strategy to rapidly generate LCB02A clinical proof of concept
